KAT6A regulates osteoclast differentiation and bone resorption through TET1-mediated TRPV4 expression
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-02 · 399 (4) · 5399-5412
DOI: 10.1007/s00210-025-04608-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 01.11.2025. Verfasst von Boran Cao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200052, China. Hauptthemen laut MEDLINE: Osteoclasts, TRPV Cation Channels, Histone Acetyltransferases, Bone Resorption. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Construction of key clinical specialties in Shanghai, High-level scientific and technological innovation projects combination of medical treatment and health care, General project of Shanghai Natural Science Foundation.
Abstract (Originalsprache)
Osteoclast differentiation plays a crucial role in osteoporosis (OP) pathogenesis, yet the regulatory mechanisms remain poorly understood. Lysine acetyltransferase KAT6A, a member of the myeloid-lymphoid or mixed-lineage leukemia (MYST) family, regulates gene expression through histone H3 acetylation. This study investigated the role of KAT6A in osteoclast differentiation and elucidated regulatory mechanisms. Serum samples from osteoporosis patients and healthy controls were analyzed for KAT6A expression. An ovariectomy (OVX) mouse model and receptor activator of nuclear factor kappa-B ligand (RANKL)-induced differentiation system using bone marrow macrophages (BMMs) and RAW264.7 cells were employed. KAT6A knockdown was achieved using short hairpin RNA (shRNA) vectors, with rescue experiments using Transient Receptor Potential Vanilloid 4 (TRPV4) and Tet1 overexpression. Osteoclast differentiation was assessed by tartrate-resistant acid phosphatase (TRAP) staining, phalloidin staining, and osteoclast marker expression analysis (TRAP, c-Fos, NFATc1). Chromatin immunoprecipitation (ChIP) assays were used to investigate transcriptional regulatory mechanisms.KAT6A was significantly elevated in osteoporosis patients compared with controls. In the OVX model, KAT6A knockdown ameliorated bone loss, improving bone volume/total volume (BV/TV), trabecular thickness (Tb.Th), and trabecular number (Tb.N), while reducing trabecular separation (Tb.Sp). KAT6A depletion suppressed osteoclast differentiation markers and reduced TRAP-positive cell formation. Mechanistically, KAT6A directly bound to the Tet1 promoter region, enhancing H3K9 acetylation and RNA polymerase II recruitment, and upregulating Tet1 expression. Tet1 associated with the TRPV4 gene region and appeared to promote its transcription, suggesting potential transcriptional regulation. Overexpression of either Tet1 or TRPV4 rescued the KAT6A knockdown-induced osteoclast differentiation inhibition. KAT6A promotes osteoclast differentiation through a regulatory cascade involving Tet1-mediated TRPV4 upregulation, which identifying KAT6A as a potential therapeutic target for osteoporosis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200052, China.
- Arthritis Institute of Integrated Traditional Chinese and Western Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
- Department of Oncology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
- Department of Orthopaedic Surgery, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200052, China. ghxlb@shutcm.edu.cn.
- Arthritis Institute of Integrated Traditional Chinese and Western Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. ghxlb@shutcm.ed…
Förderung
- Construction of key clinical specialties in Shanghai
- High-level scientific and technological innovation projects combination of medical treatment and health care
- General project of Shanghai Natural Science Foundation
- Shanghai Science and Technology Committee
- three-year action plan of shanghai traditional Chinese medicine
Zitieren
APA
Cao, B., Dai, X., & Xiao, L. (2026). KAT6A regulates osteoclast differentiation and bone resorption through TET1-mediated TRPV4 expression. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(4), 5399-5412. https://doi.org/10.1007/s00210-025-04608-8
Vancouver
Cao B, Dai X, Xiao L. KAT6A regulates osteoclast differentiation and bone resorption through TET1-mediated TRPV4 expression. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(4):5399-5412. doi:10.1007/s00210-025-04608-8
BibTeX
@article{Cao2026,
author = {Cao, Boran and Dai, Xin and Xiao, Lianbo},
title = {KAT6A regulates osteoclast differentiation and bone resorption through TET1-mediated TRPV4 expression},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {4},
pages = {5399--5412},
doi = {10.1007/s00210-025-04608-8}
}
EUVIMED